Evidence-based safety information about medication, vaccine, chemical and radiological exposures in pregnancy
CFTR modulators in pregnancy
We have published a new systematic evidence review on the safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators (CFTRm) in pregnancy. Their use has been associated with a marked increase in pregnancies among women with cystic fibrosis, but data on maternal and fetal safety is limited. This review aims to support decision-making around continuing treatment in pregnancy.
Nausea and vomiting in pregnancy
We are excited to share our animation on treatment of nausea and vomiting during pregnancy. The animation has been designed with women who do not speak English as their first language so that more pregnant women can make informed choices about healthcare. The animations can be found on our medicinesinpregnancy.org website here.
Antiseizure medication use in pregnancy
In 2025 we updated all our antiseizure medication systematic evidence reviews to include the latest published data as well as publishing three new reviews for lacosamide, zonisamide and ethosuximide use in pregnancy. All the documents can be found via the A-Z list or using the search function.
Paracetamol and Autism Spectrum Disorder
UKTIS does not support the recent claims relating to paracetamol use in pregnancy. We have released a joint official position statement with the MacDonald Obstetric Medicine Society (MOMS), the British Maternal Fetal Medicine Society (BMFMS) and the Royal College of Obstetricians and Gynaecologists (RCOG) regarding the risk of autism spectrum disorder (ASD) following paracetamol use in pregnancy. The statement can be found here.
Janus kinase inhibitors (JAK-Is) in pregnancy
We have published a new systematic evidence review on the safety of janus kinase inhibitors (JAK-Is) in pregnancy. Given the data limitations, the use of JAK-Is in pregnancy should be reserved for situations where alternative treatments, with better quality pregnancy safety data, are either not appropriate or do not provide adequate control of the maternal condition.
GLP1 receptor agonists in pregnancy
For up to date information on the use of GLP1 receptor agonists in pregnancy please see our systematic evidence review here. Data are currently limited and more information is required about their safety in pregnancy. Please encourage women who have conceived on a GLP1 receptor agonist to record their pregnancy on the MyBUMP portal.
Latest papers from the field of teratology
IQVIA study published investigating neurodevelopmental delay risks following paternal valproate use
Commentary published on the FDA panel discussion about SSRI use in pregnancy
Who are UKTIS?
UKTIS is commissioned by the UK Health Security Agency (UKHSA) and hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust to perform national surveillance of known and emerging human teratogens.
Information collected by UKTIS is recognised by the Caldicott Advisory Panel of UKHSA.